Product Introduction
Bioactivity


英文名: ASTX660

描述: ASTX660 是一种口服生物可利用的 cIAP 和 XIAP 双重拮抗剂。

体外活性: Twenty-one triple-negative breast cancer (TNBC) cell lines are treated with ASTX660 in vitro and it is found that 43% are sensitive to ASTX660.

体内活性: ASTX660 (daily oral treatment) inhibits tumor growth moderately but not a regression in HCC1806 xenografts in mice.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 47 mg/mL(87.09 mM)


关键字: ASTX660 | ASTX-660 | Inhibitor | inhibit | IAP | ASTX 660

相关产品: AZD5582 | LCL161 | AZD5582 TFA | MX69 | Acacetin | CUDC-427 | SM-164 Hydrochloride (957135-43-2 free base) | AZD5582 acetate (1258392-53-8 free base) | Phenoxodiol | Birinapant

相关库: Drug Repurposing Compound Library | Anti-Cancer Drug Library | Bioactive Compounds Library Max | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Active Compound Library | Apoptosis Compound Library | Hematonosis Compound Library | NO PAINS Compound Library | Bioactive Compound Library